SLC11A1作为胶质瘤患者免疫治疗或化疗分层指标的数据表

数据集获取（Figshare）

• 源站标题：Table_1_SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.xlsx
• DOI：10.3389/fimmu.2022.980378.s002
• 发布日期：2022-11-30
• 文件数：1 个
• 文件总体积：16.38 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_SLC11A1_as_a_stratification_indicator_for_immunotherapy_or_chemotherapy_in_patients_with_glioma_xlsx/21645578

命令行下载

curl -L -o "Table_1_SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.xlsx" "https://ndownloader.figshare.com/files/38376755"

文件清单

• Table_1_SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.xlsx（16.38 KB）

文件总体积 16.38 KB（源站 API 实测）。

数据说明

BackgroundGlioma is a fatal tumor originating from the brain, which accounts for most intracranial malignancies. Currently, Immunotherapy has turned into a novel and promising treatment in glioma patients. however, there are still few effective biomarkers to mirror the reaction to immunotherapy in patients with glioma. Therefore, we intended to elucidate the evaluable efficacy of SLC11A1 in glioma patients.
MethodsIn this study, samples from Shanghai General Hospital and data from TCGA, GEO, CGGA datasets were used to investigate and validate the relationship between SLC11A1 and the progression of glioma. We evaluated the predictive value of SLC11A1 on the prognosis of glioma with cox regression analysis. Then the relationship between immune infiltration and SLC11A1 was also analyzed. Ultimately, we performed the prediction on the immunotherapeutic response and therapeutic drugs according to the expression of SLC11A1.
ResultsExpression of SLC11A1 increased with progression and predicted unfavorable prognosis for glioma patients. The hazard ratio for SLC11A1 expression was 2.33 with 95% CI (1.92-2.58) (P This study provided evidence that SLC11A1 was a novel prognostic marker and immunotherapy response indicator for gliomas. In some cases, SLC11A1 could be an effective marker for identifying patients who might benefit from immunotherapy or chemotherapy.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2022.980378.s002（source: https://frontiersin.figshare.com/articles/dataset/Table_1_SLC11A1_as_a_stratification_indicator_for_immunotherapy_or_chemotherapy_in_patients_with_glioma_xlsx/21645578）。